ORMP

Oramed Pharmaceuticals Inc. - 10-K Summary (Fiscal Year Ended August 31, 2010)

Business Context and Reporting Period

Oramed Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the research and development of innovative drug delivery solutions, primarily an orally ingestible insulin capsule (ORMD0801) for the treatment of diabetes. The company also develops oral delivery systems for other polypeptides, including a GLP-1 analog (ORMD0901). The reporting period covers the fiscal year ended August 31, 2010. The company has no commercial product revenues and relies on equity financing and government grants to fund operations.

Key Financial Metrics

Note: R&D expenses are presented net of Israeli government grants totaling $350,198 for 2010.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by approximately $217,000 (7.9%) compared to the prior year, driven primarily by a $298,623 increase in General and Administrative expenses.
• Expense Drivers: G&A expenses rose due to increased professional, legal, and consulting fees, as well as higher stock-based compensation ($466,623 in 2010 vs. $288,338 in 2009). R&D expenses decreased slightly due to reduced purchases of clinical materials.
• Liquidity Decline: Cash and cash equivalents decreased by approximately $517,000. Short-term investments were liquidated, dropping from $1,000,000 to $100,000.
• Working Capital: Working capital decreased significantly from $2.8 million to $0.9 million, reflecting the burn rate of cash reserves.

Guidance, Outlook, Risks, and Contingencies

Going Concern: The filing explicitly states there is "substantial doubt" about the company's ability to continue as a going concern. Management estimates cash reserves are insufficient to meet liquidity requirements through August 31, 2011. The company anticipates requiring approximately $5.2 million to finance operations for the next twelve months.

Outlook and Strategy:

• Clinical Trials: The company is conducting non-FDA approved Phase 2B studies in South Africa and plans to file an Investigational New Drug (IND) application with the FDA for a Phase 2 study. Positive results were reported for Phase 2A trials in Type 1 and Type 2 diabetics.
• Partnerships: Strategy relies on securing a strategic commercial partner for late-stage (Phase III) trials and commercialization. No such partner is currently secured.
• Joint Venture: Established "Entera Bio Ltd." with D.N.A Biomedical Solutions to develop oral delivery drugs for osteoporosis. Oramed holds a 50% interest.

Risks and Contingencies:

• Financing Risk: Failure to secure additional capital could force the scaling back or termination of R&D efforts.
• Regulatory Risk: No products have received regulatory approval; clinical trials may fail or be delayed.
• Internal Controls: Management identified a material weakness in internal controls over financial reporting due to a lack of segregation of duties (CFO performs all accounting functions).
• Intellectual Property: Reliance on pending patents; risk of infringement claims or inability to secure protection.

Key Facts for Investor Verification

• Cash Runway: Verify the company's ability to raise the estimated $5.2 million needed to survive the next 12 months, given the "substantial doubt" going concern warning.
• Stock-Based Compensation: Review the significant non-cash expense ($807,826 total stock-based compensation in 2010) and the dilutive impact of outstanding options and warrants (approx. 15.6 million).
• Related Party Transactions: Confirm the terms of agreements with KNRY Ltd. (owned by CEO Nadav Kidron) and the joint venture with D.N.A Biomedical (controlled by a 10.7% shareholder).
• Government Grants: Assess the sustainability of R&D funding from the Israeli Office of the Chief Scientist and the royalty obligations attached to future product sales.
• Internal Controls: Evaluate the remediation plan for the material weakness in financial reporting controls identified by management.